FDA Requires Tumor Testing Before Treatment with Keytruda and Tecentriq in Bladder Cancer

The United States Food and Drug Administration (FDA) updated requirements for patients with advanced bladder cancer seeking treatment with Keytruda or Tecentriq. The FDA now requires patients to have their tumor tissue tested for the PD-L1 levels. Since Keytruda and Tecentriq produce anti-cancer effects through the PD-L1 pathway, the tests will help determine if patients will will benefit from either Keytruda or Tecentriq.

Read the FDA update here:

Leave a Reply

Your email address will not be published. Required fields are marked *